Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients

NCT02253277 | Completed Phase 1

• 1 other identifier: CAMN107YDE19
• Study Type: interventional
• Target: 5
• Locations: 1 country
• Sites: 4

Brief Summary

In this study it was the rationale to evaluate the safety and tolerability of the combined administration of nilotinib and increasing dose of ruxolitinib in patients with chronic myeloid leukemia and patients with Philadelphia positive acute lymphoblastic leukemia.

Conditions

Chronic Myeloid Leukemia

Keywords

CML, Ph+ ALL

Outcome Measures

Primary Outcomes (1)

• Occurrence of dose limiting toxicities (DLTs)

  Occurrence of DLTs during cycle 1

  Baseline, up to day 28 (equals first cycle)

Secondary Outcomes (3)

• Safety and tolerability profile of nilotinib and ruxolitinib administered in combination

  Baseline, up to month 12

• Trough levels of nilotinib and ruxolitinib administered in combination

  Baseline, up to month 12

• Clinical activity of nilotinib and ruxolitinib administered in combination

  Baseline and at 3, 6, and 12 months

Study Arms (1)

Nilotinib and Ruxolitinib

EXPERIMENTAL

The study included two strata, which were to be treated in parallel. The first stratum consisted of CML-patients in CP, which had been on nilotinib treatment before entering the study. These patients did not optimally respond to the previous treatment. The second stratum consisted of patients with CML in AP or BC and patients with relapsed/refractory Ph+ ALL and Ph+ ALL patients with MRD, with or without previous nilotinib treatment. Patients were treated with 300mg nilotinib BID during the escalation phase (12 months) with increasing doses of ruxolitinib. The dose expansion phase (12 months) began following the determination of the MTD of the combination and the decision to explore the cohort for confirmation of RPIID. In this phase, safety and tolerability of the MTD and/or potential RPIID was to be further evaluated, with the purpose of establishing that this dose is suitable for use in this patient group.

Drug: Nilotinib; Drug: Ruxolitinib

Interventions

Nilotinib DRUG

Nilotinib was supplied by Novartis as 150 mg and 200 mg hard gelatin capsules. Nilotinib was not dosed by weight or body surface area. Medication labels were in German and complied with the legal requirements of Germany. They included storage conditions for the drug but no information about the patient. The investigator emphasized compliance and instructed the patient to take nilotinib exactly as prescribed.

Nilotinib and Ruxolitinib

Ruxolitinib DRUG

Ruxolitinib was supplied by Novartis as 5 mg, 15 mg, and 20 mg tablets. Medication labels were in German and complied with the legal requirements of Germany. They included storage conditions for the drug but no information about the patient. The investigator emphasized compliance and instructed the patient to take ruxolitinib exactly as prescribed.

Nilotinib and Ruxolitinib

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients of the first stratum must have chronic myeloid leukemia receiving nilotinib first-line therapy or receiving second-line or subsequent-line treatment with nilotinib.
• Patients of the second stratum must have CML in AP/BC or relapsed/refractory Ph+ ALL, or be Ph+ ALL patients with MRD with or without prior nilotinib pretreatment;
• Patients must have adequate end organ function, as defined by:
• Creatinine \< 2.0 x upper limit of normal (ULN)
• Total bilirubin \< 1.5 x ULN (\< 3.0 x ULN if related to disease or polymorphism, such as Mb. Gilbert)
• ALT and AST \< 2.5 x ULN (\< 5.0 x ULN if related to disease)
• Serum lipase ≤ 1.5 x ULN
• Alkaline phosphatase ≤ 2.5 x ULN (\< 5.0 x ULN if related to disease);
• Patients must have the following electrolyte values within normal limits or corrected to within normal limits with supplements prior to the first dose of study medication:
• Potassium
• Magnesium
• Phosphate
• Total calcium (corrected for serum albumin);
• Female patients of childbearing potential (WOCBP) must have a negative serum pregnancy test within 7 days before initiation of study drug. All WOCBP must use highly effective contraceptive methods throughout and during 3 months after study;
• Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1 for patients in CP, ≤ 2 for patients in AP/BC or with relapsed/refractory Ph+ ALL or with Ph+ ALL with MRD;

You may not qualify if:

• Patient must not have evidence of active malignancy other than the existing CML or ALL
• Patient must not receive drugs that interfere with coagulation or inhibits platelet function, with the exception of aspirin ≤ 150 mg per day or low molecular weight heparin.
• Patient must not have history of platelet dysfunction, bleeding diathesis, and/or coagulopathy in the 6 months prior to screening;
• Patient must not require treatment with any strong CYP3A4 inducer or inhibitor
• Patient must not have history of hypersensitivity to any of the study drugs or to drugs of similar chemical classes and their excipients;
• Patients must not take other investigational drugs within 28 days prior to screening;
• Patient must not be pregnant or lactating at screening and/or baseline;
• Patient must not have impaired cardiac functions

Sponsors & Collaborators

• Novartis Pharmaceuticals: lead

Study Sites (4)

Novartis Investigative Site

Berlin, 13353, Germany

Location

Novartis Investigative Site

Frankfurt, 60590, Germany

Location

Novartis Investigative Site

Jena, 07740, Germany

Location

Novartis Investigative Site

Leipzig, 04103, Germany

Location

MeSH Terms

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Interventions

nilotinib; ruxolitinib

Condition Hierarchy (Ancestors)

Leukemia, Myeloid; Leukemia; Neoplasms by Histologic Type; Neoplasms; Myeloproliferative Disorders; Bone Marrow Diseases; Hematologic Diseases; Hemic and Lymphatic Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Andreas Hochhaus, Prof. Dr. med.

  Jena University Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 17, 2014
• First Posted: October 1, 2014
• Study Start: February 18, 2015
• Primary Completion: March 6, 2018
• Study Completion: April 3, 2018
• Last Updated: May 1, 2019

Record last verified: 2019-04

Data Sharing

• IPD Sharing: Will not share

Locations

DE (4)